Fifty1 Labs Partners with LUNR Aerospace to Pioneer AI-Driven Drug Repurposing for Space Medicine, Strategic Collaboration Aims to Harness AI and Orbital Access to Revolutionize Astronaut Health Solutions in a $2 Billion Market by 2032
Fifty1 Labs (OTC:FITY) has formed a strategic partnership with LUNR Aerospace to develop AI-driven drug repurposing solutions for space medicine. The collaboration aims to address critical health challenges in microgravity environments, including immune support, musculoskeletal resilience, and neuro-ocular protection.
The partnership targets the rapidly growing space medicine market, currently valued at $948.7 million in 2025 and projected to reach $1.97 billion by 2032, with an 11% CAGR. The initiative combines Fifty1 Labs' AI-driven drug discovery expertise with LUNR Aerospace's orbital delivery capabilities to develop therapeutics for astronaut health challenges.
This collaboration positions both companies to capitalize on the expanding space medicine sector, particularly in North America, where NASA recently awarded a $2.46 billion contract for astronaut health support, potentially extending to $3.6 billion through 2035.
Fifty1 Labs (OTC:FITY) ha siglato una partnership strategica con LUNR Aerospace per sviluppare soluzioni di riposizionamento farmacologico basate sull'IA rivolte alla medicina spaziale. La collaborazione mira a fronteggiare problemi di salute critici in condizioni di microgravità, quali il supporto immunitario, la resilienza muscoloscheletrica e la protezione neuro-oculare.
Il progetto punta al mercato della medicina spaziale in rapida espansione, valutato 948,7 milioni di dollari nel 2025 e stimato raggiungere 1,97 miliardi di dollari entro il 2032, con un CAGR dell'11%. L'iniziativa unisce l'esperienza di Fifty1 Labs nella scoperta di farmaci guidata dall'IA alle capacità di consegna orbitale di LUNR Aerospace per sviluppare terapie rivolte alla salute degli astronauti.
La collaborazione mette entrambe le società in una posizione favorevole per sfruttare la crescita del settore della medicina spaziale, in particolare in Nord America, dove la NASA ha recentemente assegnato un contratto da 2,46 miliardi di dollari per il supporto alla salute degli astronauti, con possibilità di estensione fino a 3,6 miliardi di dollari entro il 2035.
Fifty1 Labs (OTC:FITY) ha establecido una alianza estratégica con LUNR Aerospace para desarrollar soluciones de reposicionamiento de fármacos impulsadas por IA para la medicina espacial. La colaboración busca afrontar desafíos de salud críticos en entornos de microgravedad, incluyendo el apoyo inmunitario, la resistencia musculoesquelética y la protección neuro-ocular.
La asociación se dirige al mercado de medicina espacial, que está creciendo rápidamente y se valoró en 948,7 millones de dólares en 2025, proyectándose alcanzar 1.970 millones de dólares para 2032, con un 11% de CAGR. La iniciativa combina la experiencia de Fifty1 Labs en descubrimiento de fármacos impulsado por IA con las capacidades de entrega orbital de LUNR Aerospace para desarrollar terapias para la salud de los astronautas.
Esta colaboración coloca a ambas compañías en posición de beneficiarse del sector de medicina espacial en expansión, especialmente en Norteamérica, donde la NASA otorgó recientemente un contrato de 2.460 millones de dólares para el apoyo a la salud de los astronautas, con potencial de ampliación hasta 3.600 millones de dólares hasta 2035.
Fifty1 Labs (OTC:FITY)는 LUNR Aerospace와 전략적 제휴를 맺고 우주 의학을 위한 AI 기반 약물 재창출 솔루션을 개발합니다. 이번 협력은 미세중력 환경에서의 면역 지원, 근골격계 회복력, 신경-안구 보호 등 주요 건강 문제를 해결하는 것을 목표로 합니다.
이 파트너십은 2025년 9억4870만 달러로 평가된 빠르게 성장하는 우주 의학 시장을 겨냥하며, 2032년까지 19억7000만 달러에 달할 것으로 예측되며 연평균 성장률 11%을 보일 것으로 전망됩니다. 이 이니셔티브는 Fifty1 Labs의 AI 기반 약물 발견 역량과 LUNR Aerospace의 궤도 전달 능력을 결합해 우주비행사 건강을 위한 치료제를 개발합니다.
이번 협력은 특히 북미 지역에서 확장 중인 우주 의학 분야의 기회를 양사에 제공합니다. NASA가 최근 우주비행사 건강 지원을 위해 24억6000만 달러 규모의 계약을 체결했으며, 이는 2035년까지 36억 달러로 확대될 가능성이 있습니다.
Fifty1 Labs (OTC:FITY) a formé un partenariat stratégique avec LUNR Aerospace pour développer des solutions de repositionnement de médicaments pilotées par l'IA pour la médecine spatiale. Cette collaboration vise à répondre aux enjeux de santé critiques en microgravité, notamment le soutien immunitaire, la résilience musculo‑squelettique et la protection neuro‑oculaire.
Le partenariat cible le marché en forte croissance de la médecine spatiale, évalué à 948,7 millions de dollars en 2025 et projeté à 1,97 milliard de dollars d'ici 2032, avec un TCAC de 11%. L'initiative combine l'expertise de Fifty1 Labs en découverte de médicaments pilotée par l'IA et les capacités de livraison orbitale de LUNR Aerospace pour développer des traitements destinés à la santé des astronautes.
Cette collaboration place les deux sociétés en position de tirer parti de l'expansion du secteur de la médecine spatiale, en particulier en Amérique du Nord, où la NASA a récemment attribué un contrat de 2,46 milliards de dollars pour le soutien de la santé des astronautes, susceptible d'être porté à 3,6 milliards de dollars d'ici 2035.
Fifty1 Labs (OTC:FITY) hat eine strategische Partnerschaft mit LUNR Aerospace geschlossen, um KI-gestützte Wirkstoff-Repositionierungs‑Lösungen für die Raumfahrtmedizin zu entwickeln. Die Zusammenarbeit zielt darauf ab, kritische gesundheitliche Herausforderungen in der Mikrogravitation zu adressieren, darunter Immununterstützung, muskuloskelettale Widerstandsfähigkeit und neuro-okularer Schutz.
Die Partnerschaft richtet sich an den schnell wachsenden Markt für Raumfahrtmedizin, der 2025 auf 948,7 Millionen US-Dollar geschätzt wurde und bis 2032 voraussichtlich 1,97 Milliarden US-Dollar erreichen wird, mit einem jährlichen Wachstum von 11%. Das Vorhaben kombiniert Fifty1 Labs' KI-getriebene Expertise in der Wirkstoffforschung mit LUNR Aerospaces orbitalen Lieferfähigkeiten zur Entwicklung von Therapeutika für die Gesundheit von Astronauten.
Die Kooperation positioniert beide Unternehmen, um vom expandierenden Sektor der Raumfahrtmedizin zu profitieren, insbesondere in Nordamerika, wo die NASA kürzlich einen 2,46 Milliarden US-Dollar-Vertrag für die Unterstützung der Astronautengesundheit vergeben hat, mit einer potenziellen Ausweitung auf 3,6 Milliarden US-Dollar bis 2035.
- Partnership targets a growing space medicine market projected to reach $1.97 billion by 2032
- Positions company to compete in NASA's multi-billion dollar astronaut health support contracts
- Dual-use applications potential across aerospace, defense, longevity, and precision health sectors
- Cost-efficient approach through AI-driven drug repurposing technology
- Early-stage partnership with no immediate revenue impact
- Highly competitive market with established players like KBR
- Success dependent on LUNR Aerospace's unproven orbital delivery capabilities
VANCOUVER, British Columbia, Aug. 26, 2025 (GLOBE NEWSWIRE) -- via IBN -- Fifty 1 AI Labs, a subsidiary of Fifty 1 Labs, Inc. (OTC: FITY), has entered a groundbreaking partnership with LUNR Aerospace to develop AI-driven drug repurposing initiatives tailored for space medicine. This collaboration targets critical health challenges in microgravity, including immune support, musculoskeletal resilience, neuro-ocular protection (Spaceflight-Associated Neuro-Ocular Syndrome, or SANS), cardiovascular stability, cognitive performance, sleep optimization, and metabolic longevity, addressing the unique physiological demands of space exploration.
The partnership launches a series of pilot programs to test AI-curated, repurposed therapeutics and nutraceuticals in space-relevant conditions, offering a cost-efficient and accelerated approach to innovation. This aligns with the rapidly expanding space medicine market, valued at USD 948.7 million in 2025 and projected to reach USD 1.97 billion by 2032, driven by an
"Space exploration is pushing the boundaries of human endurance, and our partnership with LUNR Aerospace positions Fifty1 Labs at the forefront of ensuring astronaut health and performance in these extreme environments," said Paul Arora, CEO of Fifty1 Labs. "By combining our AI-driven drug repurposing capabilities with LUNR's plans for orbital infrastructure, we will not only be advancing space medicine but also unlock dual-use applications that could transform aerospace, defense, longevity, and precision health sectors."
North America leads the global space medicine market, driven by NASA's leadership and advanced healthcare infrastructure, fueling demand for sophisticated health solutions for deep-space missions. Per the Reuters article "KBR secures NASA contract worth up to
The collaboration also taps into the growing scope of space medicine, fueled by global space programs and commercial players. According to the "Global Space Medicine Market Size and Share Analysis - Growth Trends and Forecasts (2025-2032)" report by Coherent Market Insights, published on March 27, 2025, the space medicine market is estimated at USD 948.7 million in 2025 and projected to reach USD 1,969.7 million by 2032, with a compound annual growth rate (CAGR) of
By integrating AI-powered drug repurposing with space-based research, this partnership opens opportunities for dual-use innovations across multiple high-value sectors, positioning investors at the nexus of biotech and space-tech disruption. The collaboration underscores Fifty1 Labs' commitment to pushing the boundaries of precision medicine, both on Earth and beyond.
For more information about Fifty1 Labs and its innovative AI-driven solutions, visit www.fifty1labs.com.
About Fifty1 AI Labs
Fifty1 AI Labs, a subsidiary of Fifty1 Labs, Inc. (OTC: FITY), is redefining drug discovery by using AI to unlock new potential in proven medicines. By repurposing safe, off-patent compounds, we accelerate smarter therapies that improve lives, reduce costs, and create lasting value for patients, partners, and forward-thinking investors.
About LUNR Aerospace
LUNR Aerospace Corporation, commonly known as LUNR, is a Canadian space technology company headquartered in Vancouver, Canada. Founded in 2024 with the mission to advance the future of orbital access from Canada, LUNR is working to develop reliable and efficient orbital launch vehicles. By combining cutting-edge innovation with Canadian ingenuity, LUNR aims to democratize access to space for commercial, scientific, and governmental missions worldwide. For more information on LUNR, visit https://lunrcorp.com.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical facts contained in this press release, including statements regarding the potential impact, development, and timeline of AI-powered drug repurposing for antiviral therapies, the launch of exploratory AI-driven projects for pandemic readiness, and the ability of Fifty1 AI Labs' platform to transform antiviral treatment strategies and global health security, are forward-looking statements. These statements involve known and unknown risks, uncertainties, and other important factors that may cause the company's actual results, performance, or achievements to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. These risks and uncertainties include, but are not limited to, the success and timing of partnerships and projects, the efficacy and safety of repurposed treatments, regulatory approvals, and the company's ability to successfully develop and commercialize its technologies. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, please refer to Fifty1 Labs, Inc.'s filings with the OTC Markets. The company undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, except as required by law.
Contact:
Investor Relations
Fifty 1 Labs, Inc.
ir@fifty1labs.com | (877) 505-5006
www.fifty1AIlabs.com
FAQ
What is the partnership between Fifty1 Labs (OTC:FITY) and LUNR Aerospace?
What is the projected market size for space medicine by 2032?
What health challenges will Fifty1 Labs (OTC:FITY) address in space medicine?
How much is NASA's recent contract for astronaut health support worth?
What is the current market value of the space medicine sector in 2025?
